Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Article Swipe
Related Concepts
Paul W. Armstrong
,
Burkert Pieske
,
Kevin J. Anstrom
,
Justin A. Ezekowitz
,
Adrian F. Hernandez
,
Javed Butler
,
Carolyn S.P. Lam
,
Piotr Ponikowski
,
Adriaan A. Voors
,
Gang Jia
,
Steven E. McNulty
,
Mahesh J. Patel
,
Lothar Roessig
,
Joerg Koglin
,
Christopher M. O’Connor
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1915928
· OA: W3013207865
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1056/nejmoa1915928
· OA: W3013207865
Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Related Topics
Finding more related topics…